Curcumin Shows Multi-Pathway Effects in Cellular Models of Huntington’s Disease

Huntington’s disease is a monogenic neurodegenerative disorder caused by an expansion of CAG trinucleotide repeats in the HTT gene, which produces an aggregation-prone mutant huntingtin protein and drives progressive neuronal dysfunction. Because a single genetic lesion triggers a cascade of downstream defects, researchers have long sought compounds that can act on several disease-relevant pathways at once. A new study published in Molecular Biology Reports by Sushmita Singh, Ravi Vijayvargia and colleagues at The Maharaja Sayajirao University of Baroda, working with collaborators at the National Institute of Mental Health and Neurosciences in Bangalore, examined whether curcumin, the polyphenol best known as the yellow pigment of turmeric, could serve as exactly such an exploratory pharmacological tool in cellular models of the disease.

The research team set out to test curcumin against the major molecular disturbances that characterize Huntington’s disease pathogenesis: disrupted protein homeostasis, impaired mitochondrial function, oxidative stress, altered epigenetic regulation, endoplasmic reticulum stress and inflammatory signalling. Rather than focusing on a single readout, the investigators used established HD cellular models to profile the compound’s effects across these interconnected processes, an approach that reflects the growing recognition that mutant huntingtin toxicity is not confined to one cellular compartment or pathway.

One of the central findings concerns protein aggregation, a hallmark of the disease. The mutant huntingtin protein tends to misfold and clump into aggregates that burden the cell’s quality-control machinery. In the HD cells treated with curcumin, the researchers observed a reduction in mutant huntingtin aggregation. The mechanism behind this effect appears to involve autophagy, the cellular recycling system that engulfs and degrades damaged proteins and organelles. Curcumin treatment elevated autophagic clearance, giving cells a more efficient route for disposing of the aggregation-prone protein species that accumulate in the disease state.

The study also documented a striking effect on the unfolded protein response. In HD cells, curcumin reduced PERK-eIF2α signalling, a branch of the endoplasmic reticulum stress pathway that becomes chronically activated when misfolded proteins overwhelm the folding capacity of the ER. Persistent PERK-eIF2α signalling is thought to contribute to neuronal dysfunction by throttling protein synthesis and amplifying stress responses, so its attenuation by curcumin suggests that the compound helps relieve one of the key proteostasis pressures exerted by mutant huntingtin.

Mitochondrial energetics emerged as another pathway responsive to the polyphenol. Cells carrying mutant huntingtin typically show depleted ATP levels and impaired expression of genes that govern mitochondrial biogenesis and antioxidant defense. In the curcumin-treated HD cells, ATP levels increased, and the expression of Ppargc1α and Nrf1, transcriptional regulators of mitochondrial function and oxidative stress responses, was partially restored. These shifts indicate that curcumin does not merely mop up reactive molecules downstream but may help re-establish portions of the transcriptional program that keeps mitochondria functional in vulnerable neurons.

Consistent with that mitochondrial rescue, curcumin treatment reduced both mitochondrial and cytosolic reactive oxygen species. Oxidative stress is a pervasive feature of Huntington’s disease, damaging lipids, proteins and DNA and feeding forward into further mitochondrial dysfunction. By lowering reactive oxygen species in two cellular compartments simultaneously, curcumin appears to interrupt this self-reinforcing loop, complementing its effects on ATP production and mitochondrial gene expression.

Beyond proteostasis and energetics, the study reached into epigenetic territory. The researchers found that curcumin reduced H3K27 trimethylation, a histone modification laid down by the polycomb repressive complex 2 that is dysregulated in Huntington’s disease. Huntingtin itself has been shown to facilitate PRC2 function, and aberrant histone methylation patterns are thought to contribute to the transcriptional dysregulation seen in affected neurons. The observation that a small dietary polyphenol can shift this epigenetic mark in HD cells adds a mechanistic dimension to curcumin’s profile that goes well beyond its conventional description as an antioxidant.

Perhaps the most clinically resonant result came from experiments using lymphoblastoid cell lines derived from Huntington’s disease patients. In these human cells, curcumin treatment abrogated inflammatory responses. Immune activation is now recognized as an early and progressive feature of the disease, detectable even before clinical onset, and mutant huntingtin fragmentation in immune cells has been shown to track disease progression. The finding that curcumin can suppress inflammatory signalling in patient-derived cells suggests that the compound’s anti-inflammatory reputation, documented extensively in other disease contexts, extends to the peripheral immune dimension of Huntington’s disease as well.

The authors are careful to frame curcumin as an exploratory pharmacological tool rather than a ready-made therapy, and that framing matters. Curcumin’s notoriously poor bioavailability has limited clinical translation across many candidate diseases, and the present work was conducted entirely in cellular models, which cannot capture the full complexity of a progressing neurodegenerative disorder in the living brain. Nevertheless, the breadth of the observed effects is notable. A single compound that reduces mutant huntingtin aggregation, dampens ER stress, boosts autophagic clearance, restores mitochondrial ATP and gene expression, lowers reactive oxygen species in two compartments, modulates an epigenetic mark and silences inflammatory responses in patient-derived cells provides researchers with a versatile probe for dissecting which of these pathways are causally linked in mHTT toxicity.

That probe function may prove to be the study’s most durable contribution. Huntington’s disease drug development has faced significant setbacks in recent years, including disappointing results for antisense oligonucleotide trials, and the field continues to explore complementary strategies ranging from gene therapy to stem cell approaches. Against that backdrop, a well-characterized polyphenol that touches multiple validated disease pathways in parallel offers both a research instrument and a starting point for medicinal chemistry. If future studies can identify which of curcumin’s many molecular actions are most responsible for its benefits in these models, and whether improved analogues with better drug-like properties can reproduce those effects, the humble turmeric compound may yet contribute something concrete to the long effort to slow a disease that currently has no cure.

Subject of Research: Effects of curcumin on dysregulated molecular pathways in cellular models of Huntington's disease

Article Title: Evaluation of curcumin as an exploratory pharmacological tool for modulating dysregulated molecular pathways in cellular models of Huntington’s disease

Article References: Singh, S., Mehta, R., Dabhi, R., Shah, A., Bhatt, V., Purushottam, M., Sud, R., Viswanath, B., & Vijayvargia, R. (2026). Evaluation of curcumin as an exploratory pharmacological tool for modulating dysregulated molecular pathways in cellular models of Huntington’s disease. Molecular Biology Reports, 53(1), Article 1557. https://doi.org/10.1007/s11033-026-12739-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12739-1

Keywords: Huntington's disease, curcumin, mutant huntingtin, autophagy, mitochondrial dysfunction, oxidative stress, endoplasmic reticulum stress, epigenetics, inflammation, neurodegeneration, polyphenol, cellular models